INTRODUCTION
Retinal artery occlusion (RAO) causes sudden, painless visual loss and leads to irreversible profound retinal damage in the majority of cases [1] . Two types of RAO are commonly found: central RAO (CRAO) and branch RAO (BRAO). CRAO usually results in a dramatic, permanent decrease in visual function [1, 2] . BRAO leads to visual field defects corresponding to the ischemic retinal areas, and if the occlusion does not involve the fovea, visual acuity may not be impaired at all [2] .
CRAO is an ophthalmic emergency with treatment often recommended to start as soon as possible, as experimental data show that CRAO lasting for approximately 240 min results in massive, irreversible retinal damage [3] . Since the first detailed description of CRAO in 1859 by von Graefe [4] , various therapies have been proposed for the acute phase of nonarteritic CRAO and claimed to be beneficial for visual outcome: anterior chamber paracentesis [5, 6] ; ocular massage [7] ; intravenous injection of urokinase or plasminogen activator [8] ; and also local injection of plasminogen activator [9] .
However, Fraser and Siriwardena [10] found that treatments for acute nonarteritic CRAO reported in the literature were of unproven efficacy and concluded that there was currently not enough evidence to determine which, if any, interventions had beneficial effects.
Recently, studies have shown that stimulation with weak electrical currents could have positive effects on degenerative ophthalmologic diseases such as retinitis pigmentosa (RP) [11] , nonarteritic anterior ischemic optic neuropathy or traumatic optic neuropathy [12] , and also RAO [13] [14] [15] . The mechanism for these positive effects has been suggested to be a favorable regulation of neurotropic factors; electrical stimulation has been linked to the upregulation of neurotrophins in the central and peripheral nervous systems [16] [17] [18] , whereas in animal experiments, electrical stimulation has been shown to be beneficial for the survival of photoreceptors in Royal College of Surgeon's rats [19] promoting the survival of photoreceptors and improving retinal function in rhodopsin P347L transgenic rabbits [20] , rescuing ganglion cells after optic nerve injury in Wistar rats [21, 22] , and preserving retinal cells after light-induced retinal damage in Sprague-Dawley rats [23] [24] [25] .
The neuroprotective effects of electrical stimulation have been attributed to growth factors, such as insulin-like growth factor-1 [21, 26] , fibroblast growth factor-2 [27, 28] , ciliary neurotrophic factor [29, 30] , and brain-derived neurotrophic factor [21, 31] . Also, an overexpression of neuroprotective genes, e.g., B cell lymphoma-2 gene [32] , has been reported.
Moreover, electrical stimulation leads to reduced expression of some tumor necrosis factor and BAX genes; the latter are related to apoptosis signaling in retinal cells [33] . Another possible mechanism for the positive effects of electrical stimulation could be the associated increase in chorioretinal blood circulation, which has been demonstrated recently [34] . Transcorneal electrical stimulation (TES) in patients with nonarteritic anterior ischemic optic neuropathy and traumatic optic neuropathy [12] , longstanding RAO [13, 14] and BRAO [15] has demonstrated positive effects on visual acuity, visual field, and multifocal electroretinography (mfERG) in nonrandomized studies with a small number of patients.
Our recently published favorable results for TES in RP patients [11] inspired us to investigate the efficacy of TES in patients suffering from RAO in a prospective, randomized, sham-controlled, partially blinded, and Good Clinical Practice (GCP)-conforming study.
MATERIALS AND METHODS

Patients
Patients were recruited from the outpatient clinic and electronic medical records of the Centre for Ophthalmology, University of Tübingen, Germany. Inclusion criteria were age [18 years and best corrected visual acuity (BCVA) between light perception and 0.7 logMAR.
Exclusion criteria were the presence of other ophthalmologic diseases, particularly proliferative retinal diseases, such as diabetic retinopathy, retinal or choroidal neovascularization, exudative age-related macular degeneration, silicone oil tamponade, and severe general diseases. Giant cell arteritis was ruled out by detailed history, normal serum levels of C-reactive protein, and normal age-adjusted blood sedimentation rate.
Study Design
The study was performed at the Centre for Ophthalmology, University of Tübingen, Germany. The protocol was approved by the local ethics committee. The physicians who performed all other examinations and TES were not blinded to study treatment because they were responsible for setting the stimulation parameters.
Clinical Examinations
At all nine visits, ophthalmologic examinations were performed: BCVA assessment using a 
Determination of EPT and TES
TES and assessment of EPT were performed using a neurostimulator (Twister Ò ; Dr. Langer GmbH, Waldkirch, Germany) and a single-use sterile DTL-electrode (Fig. 1) . A gold-plated cup electrode was used as a counter electrode, and fixed on the ipsilateral temple (Fig. 1) . EPT was determined at all nine visits over a range of frequencies.
The threshold was defined as the minimal electric current that elicited phosphene perception anywhere in the visual field. An alternative forced choice method was used for verification. The neurostimulator was modified by the manufacturer to limit current output to 10 mA with increments starting from 1 lA.
Impedance of the electrodes was tested each time prior to stimulation and at various intervals during stimulation using the machine's built-in algorithm; impedance did not exceed 5 kX.
Measurements were performed in darkness with a very dim indirect light produced by the shielded computer screen.
To avoid dark adaptation, the light was switched on periodically (ca. every 60-90 s) [39] . Full darkness was necessary to allow perception of the very subtle phosphenes. The threshold at 20 Hz was determined three times, and the average was taken at each study visit for the calculation of individual stimulation strength according to the treatment group. TES was applied with 10 ms rectangular biphasic current pulses (5 ms positive, directly followed by 5 ms negative) at 20 Hz for 30 min once a week for 6 consecutive weeks.
Data Analysis
Statistical analyses were performed using the JMP Ò statistical software (version 8.02, SAS Institute, Cary, NC, USA). ERG data analysis was performed using previously described software [40] ; the slope of the initial part of the a-wave was calculated and compared to evaluate photoreceptor activity [41] . Intra-individual differences were calculated for each patient between baseline and follow-up visits.
A comparison between treatment groups was then performed using the method of restricted maximum likelihood (REML) to estimate the development of parameters under treatment for each group. To compare groups, the Tukey-Kramer post hoc test analysis was applied with a significance level of P\0.05.
RESULTS
Thirteen patients with nonarteritic RAO were enrolled (12 patients with CRAO and one patient with BRAO, age range 25-84 years, median 74 years). In total, 20 patients were screened for study participation and seven patients were excluded from the study because they were not able to deliver repeatable results in the visual field examination due to poor fixation. RAO was diagnosed 10 days to 17 months (median 11 months) prior to inclusion. Table 1 shows detailed characteristics for all patients. The numbers of patients assigned to the treatment groups were: 0 mA TES (sham), n = 3; 66% of the patients' individual EPT at 20 Hz (60%), n = 5, and 150% of the patients' individual EPT at 20 Hz (150%), n = 5.
All 13 patients completed the entire study. TES using DTL-electrodes was well tolerated, as reported previously [11, 39] . No ocular or systemic AEs were observed, except for foreignbody sensation after TES (n = 3).
All raw data and REML values are listed in Table 2 ; excerpts follow in this section. At the beginning, three patients reported phosphenes only at some of the tested frequencies (20 and 40 Hz) despite stimulation currents up to 4 mA; a level at which unpleasant sensations, such as a twitch in the eyelid, were reported. In the course of the study in two of these patients, determination of EPT was possible at all tested frequencies, whereas in one patient phosphenes could only be evoked at 20 Hz at the end of the study.
At all visits and in all patients
No statistically significant differences were detected in visual field parameters ( Table 2) .
The mean defect, the mean sensitivity in static visual field, and the area of kinetic visual field did not differ significantly between the groups; calculation of the changes in the area of the kinetic visual field in the 150% treatment group failed because the visual field was not recordable in four patients at baseline (Table 2) . However, in some of the treated patients, an enlargement of visual field area was observed. Figure 2 shows fundus photographs and the development of visual field area in two selected patients in the 150% treatment group. RAO was diagnosed in the first of these patients at 7 months and in the second of these patients at 6 months before study enrollment.
During study visits no significant differences were observed between the groups for amplitudes and implicit times in the ERG measurements under dark-or light-adapted conditions ( Table 2 ). There were, however, statistically significant changes (P = 0.03) in the a-wave slope of the high-intensity flash 
DISCUSSION
Recently, studies with TES in humans have shown that TES is safe and can exhibit positive effects in patients with degenerative retinal diseases [11] [12] [13] [14] [15] . In particular, a shamcontrolled pilot study in RP showed some In 2010, Robles-Camarillo et al. [14] investigated the effects of TES on low vision in patients with CRAO. In the 2-month study, To the authors' knowledge, the present study is the first randomized, sham-controlled, and partially blinded study to investigate TES as a potential treatment in patients with RAO. The specific stimulation parameter was chosen due to the fact that the lowest EPT was observed at In the 150% treatment group, a statistically significant increase in the scotopic a-wave slope was detected. As the a-wave slope is regarded as the electrophysiologic representation of the phototransduction process by the photoreceptors [43] [44] [45] [46] , these results indicate an improvement in photoreceptor activity during TES treatment. All other tested parameters failed to show statistically significant improvements. A failure to reach statistical significance may have been due to the very small sample size, with only three to five patients in each group. It may, however, also have been due to the short study period of only six stimulation sessions in an attempt to treat very profound retinal damage; such damage usually has a very poor prognosis. In contrast to this, in the present study with 24 RP patients [11] , significant improvements were found in clinically relevant parameters, such as visual field area and scotopic b-wave amplitude, under the same study parameters, but had the chance to examine a considerably larger study population. Statistical significance would not have been reached with smaller sample sizes as recalculations of the present data have shown.
In the present study subgroup analysis of data was not done because the groups were small, although an improvement in two longstanding cases is in accordance with previous reports by Inomata et al. [13] . It should be emphasized here that the cases included in the Inomata et al. [13] study and all other previous studies mentioned [14, 15] were based on uncontrolled series with a limited strength of evidence. The possibility that the present findings may have been biased by a potential imbalance in the study groups, such as differing extent and severity of retinal damage, and inconsistent timing of TES treatment, cannot be completely eliminated.
As a statistically significant clinical effect from the present data could not be shown, TES cannot be currently recommended as a treatment for CRAO or BRAO. Hayreh and Zimmerman [1] reported that without any treatment, an improvement in visual acuity and visual field is observed in only 6% of eyes with nonarteritic CRAO. However, the visual outcome in CRAO patients using existing treatments is unsatisfactory; various studies of new treatments for CRAO have shown no significant differences in the visual outcome between treated and untreated patients [6, [47] [48] [49] . Considering the lack of scientifically justifiable treatment options for BRAO and CRAO, and taking into account the limitations of the present study (short duration, small sample size) and the statistically significant improvement detected in a-wave slopes, further investigation is warranted to explore the potential of TES for these conditions. Any further studies on the therapeutic value of TES should retain the stringent use of a sham control, as used in the present study, and maintain study groups as homogeneously as possible. It may be possible that the initiation of treatment with TES very shortly after the onset of RAO might have a clearer effect on the course of the disease.
In conclusion, TES provides several potential advantages over intravitreal injections or surgical interventions, e.g., minimal
invasiveness. Furthermore, TES most probably generates low treatment costs, and the simplicity of the concept also means considerable ease of use for both the examiner and the patient. Therefore, it is conceivable that patients may be allowed a stimulation device at home.
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